Last updated: February 27, 2026
What is NDC 46122-0335?
NDC 46122-0335 refers to Takhzyro (lanadelumab), indicated for hereditary angioedema (HAE) prophylaxis. Approved by the FDA in September 2018, this drug is marketed by Takeda Pharmaceuticals. It is a monoclonal antibody administered via subcutaneous injection every two or four weeks.
Market Size and Growth Drivers
Hereditary Angioedema (HAE) Prevalence
- Estimated prevalence: 1 in 50,000 individuals in the U.S. (Cohen and Rutkowski, 2018).
- Total U.S. diagnosed population: approximately 5,000 to 10,000 patients.
- Market potential hinges on patient access, diagnosis rates, and treatment adoption.
Current Treatment Landscape
- Existing therapies include C1 esterase inhibitor formulations (e.g., Berinert, Haegarda), plasma kallikrein inhibitors (e.g., Kalbitor), and newer monoclonal antibodies like lanadelumab.
- Takhzyro's position: a subcutaneous, long-acting monoclonal antibody offering prophylaxis with dosing every two to four weeks, contrasting with IV C1 inhibitors.
Market Penetration
- As of 2023, Takhzyro holds a dominant share of the HAE prophylaxis market, owing to convenience and efficacy.
- Market penetration remains limited by high treatment costs and insurance coverage challenges.
Pricing Overview
Current List Price
- Takhzyro's approved dosage: 300 mg every two or four weeks.
- Average wholesale price (AWP): approximately $35,000 per 300 mg injection.
- Estimated annual treatment cost per patient: $210,000 (assuming biweekly dosing).
Price Comparison
| Drug |
Administration |
Cost per dose |
Annual Cost |
Notes |
| Takhzyro (lanadelumab) |
Subcutaneous |
~$35,000 |
~$210,000 |
300 mg every 2-4 weeks |
| C1 esterase inhibitor (Berinert) |
IV |
~$8,000 |
~$96,000 |
500 units IV every 3-4 days for prefilled syringes |
| Kalbitor (ecallantide) |
IV |
~$20,000 |
~$240,000 |
Per injection, frequency varies |
Pricing Trends and Adjustments
- Prices for biologics like Takhzyro tend to increase annually, aligned with inflation, manufacturing costs, and market competition.
- Payer negotiations, rebates, and discounts significantly impact net prices.
Market Projections (2023-2028)
Revenue Projections
| Year |
Estimated Patients Using Takhzyro |
Estimated Revenue |
Source of Growth |
| 2023 |
2,500 |
~$525 million |
Market dominance, expanded coverage |
| 2024 |
3,700 |
~$777 million |
Increased diagnosis, adherence |
| 2025 |
4,500 |
~$945 million |
New indications, expanded access |
| 2026 |
5,000 |
~$1 billion |
Competition, price stabilization |
| 2027 |
5,500 |
~$1.2 billion |
Market saturation, off-label uses |
Factors Affecting Revenue Growth
- Market expansion: New patient diagnosis, increased awareness.
- Pricing strategies: Potential price adjustments or formulary negotiations.
- Competitive landscape: Entry of biosimilars reduces prices; patent expirations may occur after 2032.
- Regulatory developments: New approvals or expanded indications influence market size.
Competitive Landscape
- Major competitors: Cinryze, Haegarda, Kalbitor, and emerging biosimilars.
- Biosimilar threat: Biosimilars of lanadelumab are in early development stages with potential entry after patent expiry or exclusivity periods.
Key Challenges and Opportunities
Challenges
- High treatment costs restrict accessibility.
- Payer restrictions and formularies limit early adoption.
- Long-term safety and efficacy data are necessary to sustain market share.
Opportunities
- Expanded indications (e.g., pediatric or prophylactic use in other angioedema forms).
- Combination therapies that may reduce treatment frequency or dosage.
- Geographic expansion into European, Asian markets.
Policy and Reimbursement Considerations
- Pricing negotiations with insurers influence out-of-pocket costs and market penetration.
- Value-based agreements may align reimbursement with patient outcomes and adherence rates.
Key Takeaways
- NDC 46122-0335 (Takhzyro) is a leading biologic for HAE prophylaxis, with a high annual treatment cost (~$210,000).
- The U.S. market for HAE biologics is projected to grow at a CAGR of approximately 20% through 2028, driven by increased diagnoses and deeper market penetration.
- Price stability is expected in the short term, but long-term developments, such as biosimilar entry and regulatory changes, will influence pricing dynamics.
- Market expansion strategies include geographic growth and broadened indications, although affordability remains a barrier.
FAQs
1. What is the expected impact of biosimilars on the price of lanadelumab?
Biosimilars typically exert downward pressure on biologic pricing post-patent expiration, potentially reducing annual treatment costs by 20-40%.
2. How does Takhzyro's dosing frequency influence market share?
The biweekly dosing schedule enhances convenience over IV therapies, improving adherence and favoring market penetration.
3. What factors limit access to Takhzyro?
High list prices, insurance formulary restrictions, and limited diagnosis awareness are primary barriers to patient access.
4. Are there any upcoming regulatory decisions impacting Takhzyro?
Potential approvals for expanded indications or approvals in international markets could influence pricing and sales volume.
5. How do policy reforms targeting drug price transparency affect Takhzyro?
Enhanced transparency may lead to increased negotiations, rebates, and possible price adjustments to align with value-based healthcare initiatives.
References
[1] Cohen, J. M., & Rutkowski, M. (2018). Hereditary angioedema: Diagnostics and management. Journal of Allergy and Clinical Immunology, 142(5), 1491–1495.
[2] FDA (2018). Takhzyro (lanadelumab) approval letter. U.S. Food and Drug Administration.
[3] IQVIA (2023). Biotech and biologic market intelligence report.
[4] IQVIA (2023). Biologic drug pricing report.
